Andrew Bab is of counsel in the firm’s New York office. Mr. Bab is the former Co-Chair of the Healthcare & Life Sciences Group and a member of the firm’s Mergers & Acquisitions and Private Equity Groups. Mr. Bab has worked extensively on public and private acquisitions, divestitures and joint ventures, including cross-border transactions for both private equity and corporate clients, as well as licensing arrangements and other corporate transactions. He has experience across many industries but is particularly active in the healthcare and life sciences sectors. In addition, he frequently advises Deutsche Bank, Guggenheim Securities, J.P. Morgan Securities, Morgan Stanley and other investment banks on major M&A transactions. Mr. Bab was named a Top Advisor Lawyer in North America by MergerLinks (2021) for his work on financial advisory representations. Mr. Bab also helped lead The Deal’s “Private Equity Deal of the Year” (representing TPG Capital and Welsh, Carson, Anderson & Stowe, together with Humana, in their $4.1 billion acquisition of Kindred Healthcare) and The Deal’s “Healthcare Deal of Year” (representing Allergan in its divestitures of Zenpep and Brazikumab, and J.P. Morgan Securities as financial advisor to Allergan in AbbVie’s $63 billion acquisition of Allergan).
Mr. Bab has been recognized for M&A, healthcare and private equity buyouts by The Legal 500 US (2015–2024), where he has been described as a “leader in healthcare transactions.” He has also been recognized as Law360’s Healthcare MVP (2018). Clients have referred to him as “one of the sharpest legal minds [they] have ever worked with” and have noted that “[h]e consistently impresses with his legal and business instincts.” Mr. Bab has been twice named to Lawdragon’s “500 Leading Lawyers in America” list (2018 & 2021), and is recognized as “Life Sciences Star” (2018-2020) by LMG Life Sciences and as a leading M&A and private equity lawyer by IFLR1000 (2022 & 2023) and Best Lawyers (2016 & 2021).
Mr. Bab has written prolifically on a variety of M&A and corporate governance-related topics. He is the author of “Spike in contingent value rights,” Westlaw (January, 2024). He is the co-editor of and contributor to the annual Health Care Mergers and Acquisitions Answer Book (Practising Law Institute, 2020), an extensive reference guide addressing structuring, regulatory, due diligence and documentation issues, among other things, in healthcare M&A and licensing deals. He is the co-author of “Reviewing Calif. Push To Restrict Private Equity In Healthcare,” Law360 (April, 2025); “Top 10 Healthcare And Life Sciences Issues To Watch In 2025,” Law360 (February, 2025); “Special Committee Midyear Report,” Harvard Law School Forum on Corporate Governance and HLS Forum on Corporate Governance (August, 2024); “Debevoise Discusses FTC Focus on Private Equity,” CLS Blue Sky Blog (June, 2022); “Debevoise & Plimpton Discusses SEC’s Proposed SPAC Rules and Investment Banks,” CLS Blue Sky Blog (May, 2022); “Special Committee Report,” Harvard Forum on Corporate Governance (March, 2022); “Sponsor-Backed PIPEs Can Aid In The Race For Liquidity,” Law360 (May, 2020); “A Post-Election Survey Of The Health Care Ecosystem,” Law360 (November, 2018); “Fourth Circuit Decision Casts Doubt on State Efforts to Regulate Drug Pricing,” Bloomberg Law (May, 2018); “Perpetually Liable? What the California Supreme Court Decision Means for Innovator Pharmaceutical Companies,” Toxics Law Reporter (February, 2018); “A Look at Recent Efforts to Contain Health Care Costs,” Law360 (January, 2018); “How Tax Reform Could Impact the Health Care Industry,” Law360 (November, 2017); “How Section 1332 Waivers Could Impact Health Care Reform,” Law360 (July, 2017); “Health Care Winners And Losers From The Better Care Act,” Law360 (June, 2017); “Shining a Light on GOP Plan for Health Care Reform,” Law360 (March, 2017); “The Outlook for the Pharmaceutical Industry under Trump,” Law360 (January, 2017); “The Outlook on Drug Pricing: At What Cost?,” Law360 (December, 2016); “Key Issues In U.S. Going Private Transactions,” The M&A Lawyer (April, 2016); and “Lot Of Inversion Talk, But Do You Know the Basics?” Law360 (August, 2014). Mr. Bab is the author of “INSIGHT: A Surprise in the PIPE Dream—Two-Class Accounting,” Bloomberg (July, 2020); “Got Financing? You May Have to Extend Your Tender Offer,” The Harvard Law School Forum on Corporate Governance and Financial Regulation (April, 2013); “Contingent Value Rights in Healthcare M&A,” Insights (April, 2011); “Poison Pills,” The Harvard Law School Forum on Corporate Governance and Financial Regulation (April, 2011); and “A New Worry,” IR Magazine (2008). He is a co-author of “Soft Dollars and Other Means of Obtaining Business,” a chapter in the Practising Law Institute treatise Broker-Dealer Regulation (2008); “SEC Proposes Amendments to Cross-Border Tender and Exchange Offer and Business Combination Rules,” BNA Securities Regulation & Law (2008); “Tender Offers: Back in Business,” Corporate Governance (2007); and “Gun Jumping Case vs. Qualcomm Shows Risks for Betrothed Companies,” Corporate Governance (2006). Mr. Bab is the author of “Contingent Value Rights,” Insights (2001) and the co-author of several articles published in The Deal, including “The Revlon Standard” (2007), “Booby Traps” (2003) and “Nerve Tonic” (2003). Mr. Bab is also a frequent speaker on legal developments affecting mergers and acquisitions and on healthcare-related issues.
Mr. Bab joined Debevoise as an associate in 1997 and became a partner in 2002. Mr. Bab received his B.A. magna cum laude from Yale University in 1986 and his J.D. in 1992 from Columbia Law School, where he was a Stone Scholar and book review editor of the Law Review. From 1992 to 1993, Mr. Bab served as law clerk to the Hon. Thomas J. Meskill, U.S. Court of Appeals for the Second Circuit. From 1986 to 1989, Mr. Bab was an investment banker at Lazard Frères & Co.